doxapram has been researched along with Developmental Disabilities in 2 studies
Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.
Developmental Disabilities: Disorders in which there is a delay in development based on that expected for a given age level or stage of development. These impairments or disabilities originate before age 18, may be expected to continue indefinitely, and constitute a substantial impairment. Biological and nonbiological factors are involved in these disorders. (From American Psychiatric Glossary, 6th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " There was a marked difference in the cumulative dosage and duration of doxapram therapy used for apnea of prematurity (total dose 2233 +/- 1927 mg vs 615 +/- 767 mg, P < ." | 7.71 | Isolated mental developmental delay in very low birth weight infants: association with prolonged doxapram therapy for apnea. ( Demianczuk, N; Etches, PC; Robertson, CM; Sreenan, C, 2001) |
| " There was a marked difference in the cumulative dosage and duration of doxapram therapy used for apnea of prematurity (total dose 2233 +/- 1927 mg vs 615 +/- 767 mg, P < ." | 3.71 | Isolated mental developmental delay in very low birth weight infants: association with prolonged doxapram therapy for apnea. ( Demianczuk, N; Etches, PC; Robertson, CM; Sreenan, C, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lando, A | 1 |
| Klamer, A | 1 |
| Jonsbo, F | 1 |
| Weiss, J | 1 |
| Greisen, G | 1 |
| Sreenan, C | 1 |
| Etches, PC | 1 |
| Demianczuk, N | 1 |
| Robertson, CM | 1 |
2 other studies available for doxapram and Developmental Disabilities
| Article | Year |
|---|---|
Doxapram and developmental delay at 12 months in children born extremely preterm.
Topics: Case-Control Studies; Developmental Disabilities; Doxapram; Female; Humans; Infant, Newborn; Infant, | 2005 |
Isolated mental developmental delay in very low birth weight infants: association with prolonged doxapram therapy for apnea.
Topics: Apnea; Case-Control Studies; Cerebral Hemorrhage; Child Development; Developmental Disabilities; Dox | 2001 |